When is a near flat trend a good trend? Right now.

Keeping drug trend in check is tough. When we can show our clients a Medicaid drug trend that’s virtually flat – three years in a row – that’s a huge victory

July 22, 2019
Thanks to skyrocketing pharmacy costs, keeping drug trend in check has become more difficult than ever. That’s why we, and our clients, view an essentially flat three-year Medicaid drug trend as a huge victory. We’ve been able to fight against high drug costs by using our wide range of cost-saving tools.

Pushing back against rising trends

In a time where drug costs are rising at unprecedented rates, maintaining solid drug trend numbers is no easy task. Since 2016, our data show we’ve stayed on top of our game by maintaining an essentially flat Medicaid drug trend¹ (despite a 6.5% national Medicaid drug spend increase²). At the same time member satisfaction scores have stayed high.³ This shows that we have the tools to manage Medicaid costs consistently and effectively:

  • Through the use of sophisticated fraud, waste and abuse programs, we removed $17.5 million of inappropriate use since 2016
  • By encouraging the use of generics (87.4% GUR in 2018), we provide cost effective care for more members
  • Since 2017, we negotiated drug and network savings of $65.5 million to provide members with the medicines they need at a lower administrative cost

Effective clinical programing tailored to the unique needs of the Medicaid population has reduced program costs $390 million since 2016.

Total drug trend for 2016-2018: 0.3%¹

Making a difference in the Medicaid space

The rise in drug costs isn’t expected to slow anytime soon. But we have the people and tools in place that will help us to evolve along with the Medicaid marketplace, because our main purpose is to get people the medicine they need to feel better and live well.

  1. Trend methodology Represents the change in 2016 vs 2018 for Prime’s Medicaid book of business for Total Costs (plan + member PMPM) inclusive of network discounts + tax + dispensing fees minus total supplemental rebates. Calculations include Medicaid populations with 12 months of 2016 and 2018 data. Geographic and population weighting was applied to book of business calculations using the 2018 state-by-state population proportions. Trend analyses in this report were prepared and reviewed by Prime’s actuarial team.
  2. Internal Prime analysis and available Medicaid Managed Care comparison data retrieved from Medicaid.gov state drug utilization database. Data through 2018.
  3. Prime internal member satisfaction survey. Member overall satisfaction with their Medicaid drug plan: 92%

Related news


April 5, 2024

LISTEN NOW: Revolutionizing Healthcare: Prime & Capital Rx’s Game-Changing Alliance – Pharmacy Friends podcast

In this special episode of the Pharmacy Friends podcast, the CEOs of Prime Therapeutics, Mostafa Kamal, and Capital Rx, AJ Loiacono, join Michael Passanante, SVP of Marketing & Communications at Capital Rx, to share the story behind the strategic alliance between the organizations and their vision to reimagine pharmacy.


March 26, 2024

Announcing the new issue of Prime’s managed care report, featuring the latest trends and updates in medical and pharmacy benefits

Prime Therapeutics/Magellan Rx (Prime/MRx) today launched the spring edition of Magellan Rx Report…


March 19, 2024

Healthcare Businesswomen’s Association names Simone Ndujiuba and Jacki Shugart among 2024 Rising Stars 

Prime Therapeutics/Magellan Rx’s Director of Clinical Strategy and Innovation Simone Ndujiuba and Senior Program Manager Jacki Shugart honored for female leadership in the health care industry